Latest Articles

  • Surgical and procedural management of benign prostatic hyperplasia
    Sameer Gadani, MD, Ihab Haddadin, MD, Justin Guan, MD, Michael Bergen, MD and Abraham Levitin, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 83; DOI: https://doi.org/10.3949/ccjm.91c.02003
  • Management of venous thromboembolism in patients with active cancer
    Heloni M. Dave, MBBS and Alok A. Khorana, MD, FACP, FASCO
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 109-117; DOI: https://doi.org/10.3949/ccjm.91a.23017

    The authors review the presentation and diagnosis of venous thromboembolism in patients with cancer and present an approach to treatment that aims to balance the bleeding risk from anticoagulation with the risk of recurrent thrombosis.

  • von Willebrand disease: A guide for the internist
    Varinder Kaur, MD, Omar Elghawy, MD, Saarang Deshpande, MD and David Riley, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 119-127; DOI: https://doi.org/10.3949/ccjm.91a.22033

    The pathophysiology of von Willebrand disease, its subtypes, common presentations of each subtype, diagnostic testing, and management of clinical manifestations of the disease are reviewed.

  • Diagnosis and management of pancreatic cystic lesions for the non-gastroenterologist
    Diagnosis and management of pancreatic cystic lesions for the non-gastroenterologist
    Arjun Chatterjee, MD, Tyler Stevens, MD, FACG, FASGE and Prabhleen Chahal, MD, FACG, FASGE
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 96-102; DOI: https://doi.org/10.3949/ccjm.91a.23019

    A summary of current guidelines from several organizations on the diagnosis and surveillance of pancreatic cystic lesions.

  • Hypertension and severe hyperreninemia in a young man
    Joshua M. Leisring, MD, Jason Lyou, MD, Eshetu Obole, MD and Amy A. Yau, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 103-108; DOI: https://doi.org/10.3949/ccjm.91a.23055

    A 29-year-old man with blood pressure measurements of 152/118 mm Hg and 156/116 mm Hg at 2 separate clinic visits is started on combination antihypertensive therapy and undergoes evaluation for secondary causes of hypertension.

  • Late complications after allogeneic hematopoietic cell transplant
    Pelin Batur, MD, FACP, MSCP
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 19; DOI: https://doi.org/10.3949/ccjm.91c.01001
  • Consumer-grade wearable cardiac monitors: What they do well, and what needs work
    Consumer-grade wearable cardiac monitors: What they do well, and what needs work
    Abdilahi Mohamoud, MBBS, Joseph Jensen, MD and Kevin G. Buda, DO
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 23-29; DOI: https://doi.org/10.3949/ccjm.91a.23030

    The authors review common consumer-grade wearables, including the accuracy of these monitors compared with medical-grade devices, and present an approach to managing rate or rhythm abnormalities identified on at-home monitoring.

  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Osamah Z. Badwan, MD, Lorenzo Braghieri, MD, Warren Skoza, MD, Ankit Agrawal, MD, Venu Menon, MD and W. H. Wilson Tang, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 47-51; DOI: https://doi.org/10.3949/ccjm.91a.23034

    Evidence from clinical trials supports starting these medications as early as possible in patients hospitalized with acute decompensated heart failure who do not have clear contraindications to them.

  • 2023 Update in ambulatory general internal medicine
    Jason T. Alexander, MD, Simran K. Singh, MD, Sachin D. Shah, MD, Brianna Lambert, MD and Jeremy P. Smith, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 40-46; DOI: https://doi.org/10.3949/ccjm.91a.23056

    Topics reviewed include prevention of chronic kidney disease progression, diet for preventing secondary cardiovascular disease, prevention of kidney-stone recurrence, drug therapy for weight loss, and cholesterol management.

  • Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting
    Shrouq Khazaaleh, MD, Mohammad Alomari, MD, Mamoon Ur Rashid, MD, Daniel Castaneda, MD and Fernando J. Castro, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 33-39; DOI: https://doi.org/10.3949/ccjm.91a.23015

    Malignancy develops in only a small minority of patients with gastric intestinal metaplasia. Recognition of clinical, endoscopic, and histologic features linked with cancer development is critical to identifying patients who require endoscopic surveillance.

Pages